FDA Oncology Announcements

Anthracycline × Clear all

5 Announcements

FDA approves brentuximab vedotin in combination with chemotherapy for pediatric patients with classical Hodgkin lymphoma

Drugs: Adcetris (brentuximab vedotin) · Anti-CD30 antibody-drug conjugate, doxorubicin · Anthracycline
Condition: Lymphoid

FDA Approves Gemtuzumab Ozogamicin for CD33-positive AML

Drugs: Mylotarg (gemtuzumab ozogamicin) · Anti-CD33 antibody-drug conjugate, daunorubicin · Anthracycline, cytarabine · Pyrimidine analog
Condition: Myeloid

FDA approves liposome-encapsulated combination of daunorubicin-cytarabine for adults with some types of poor prognosis AML

Trial: 301
Drug: VYXEOS (daunorubicin and cytarabine) · Anthracycline
Condition: Myeloid

Doxorubicin Hydrochloride Liposome (Injection)

Drug: doxorubicin hydrochloride liposome · Anthracycline
Conditions: GynecologicSarcoma

FDA Approves Doxorubicin HCl

Drug: Doxil (doxorubicin HCl liposome) · Anthracycline
Condition: Plasma cell